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Background: Wound healing is a complex process, with many potential factors that can
delay or complicate healing. Bacterial infection is one of the most dangerous complica-
tions once the skin barrier is destroyed. The search for optimal treatment of chronic and
infectedwoundsisanongoingchallengeforhealthcareprofessionals.Methods:Thisar-
ticle discusses recent ﬁndings in the ﬁeld of wound antiseptics, its antibacterial efﬁcacy,
cell toxicity, and compatibility with wound dressings. Results: Skin antiseptics are daily
usedforwoundcleansingtoreducethebacterialburden.However,thereislittleevidence
concerning the antimicrobial efﬁcacy, cytotoxicity of host cells, and compatibility with
commonly used wound dressings. Recent ﬁndings show high toxicity and signiﬁcant
incompatibilities with wound dressings for some antiseptics. Conclusion: Antiseptics
are widely used in hospitals worldwide to reduce, inactivate, or eliminate potentially
pathogenic microorganisms. Current studies show that widely used wound antiseptics
show relevant cytotoxicity and cross-reactivity with certain wound dressings. Future
research should particularly focus on cytotoxicity, mechanisms of bacterial resistance
toward skinantiseptics and wound irrigants, as well as compatibility and cross-reactivity
with wound dressings.
Surgeons are constantly challenged to ﬁnd the optimal treatment of difﬁcult-to-heal
wounds,suchaschroniculcers,trauma-inducedwounds,anddeepburns.Openwounds,par-
ticularly in diabetic and immunosuppressed patients, are susceptible to invading pathogens
such as bacteria. Chronic wounds present an attractive environment for bacterial infection,
andmorethan80%oflegulcersarecolonizedbybacteria.1,2 Bacterialcolonizationisasso-
ciated with delayed wound healing and causes severe morbidity from sepsis and multiorgan
failure.3,4 In the United States, delayed wound healing and bacterial infection due to dia-
betes are the leading causes of nontraumatic amputations (approximately 71,000 per year
or 190 per day).5,6 At present, Staphylococcus aureus is the most common single isolate
in chronic wounds (76% in foot ulcers) leading to impaired wound healing.7 Methicillin-
resistant S aureus (MRSA) has become endemic in some hospitals,8 and in 2002, the ﬁrst
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clinical isolate of vancomycin-resistant S aureus was identiﬁed in a diabetic patient with a
foot ulcer.7,9
Primary strategies used to prevent and treat wound infection include systemic antibi-
otics and topical antiseptics/antibiotics. Insufﬁcient accumulation in the soft tissue is still
a major limitation of systemic antibiotics. Furthermore, systemic antibiotics struggle with
increasing bacterial resistance and wound colonization with multiresistant strains.3,8 Thus,
their clinical employment remains controversial.10
Topical antiseptics therefore play a key role for the treatment of wounds in current
clinical practice. The philosophy behind local delivery of skin antiseptics is to raise tissue
levels of antimicrobials to a level where sensitive and relatively insensitive organisms are
inhibited and to avoid potential systemic side effects of high-dose antibiotics.
The ﬁrst modern, chemically derived antiseptic agent was discovered by Friedlieb Fer-
dinand Runge in 1834, describing the structure and properties of carbolic acid (phenol).11
A further monumental advance toward the improvement of wound-healing outcome came
from the work of Joseph Lister. The famous surgeon was the ﬁrst to employ this striking
agent in March 1865 in a complicated case of tibia fracture.12,13 In 1867, he described his
technique for the use of carbolic acid spray for surgical antisepsis and direct prophylaxis
of high-risk wounds.12,13 Within approximately 20 years, the aseptic techniques of Sem-
melweis and surgical antisepsis based on Lister’s principles became the standard of care.
In 1919, Alexander Fleming stated, “Antiseptics will only exercise a beneﬁcial effect in a
septic wound if they possess the property of stimulating or conserving the natural defensive
mechanism of the body against infection.”(p.127) He further proclaimed that in estimating
the value of an antiseptic, it is more important to study its effects on tissues than any effects
on bacteria.14
Because antiseptics often have to be applied on human skin and wounds for therapy, it
is important to evaluate their efﬁcacy and the possible cytotoxicity. However, this important
fact has been neglected in the past and still little is known about the cytotoxicity of
clinically used skin antiseptics to date. Furthermore, compatibility of wound dressings with
skin antiseptics is hardly investigated to date. This fact seems to be alarming since wound
dressings present a huge market and these products are used widely by different healthcare
professionals.
ANTIBACTERIAL EFFICACY
In a recent study, we investigated antibacterial efﬁcacy of 5 commonly used local
antiseptics.15 Octenisept (octenidine), Lavasept, Prontosan (polyhexamethylene biguanide
[PHMB]), Braunol, and Betaisodona (povidone-iodine) were tested for their antibacterial
activity against 2 gram-positive (S aureus and Enterococcus faecalis)a n d2g r a m - n e g a t i v e
(Pseudomonas aeruginosa and Escherichia coli)s t r a i n s . Therefore, different dilutions
(1%–20%) of the antiseptic solutions were investigated and minimal inhibitory concentra-
tion was determined. The analyzed bacterial strains were susceptible, in different degrees,
to all the antibiotics tested, showing that all 5 antiseptics possess antibacterial effects.
However, differences in their speciﬁc effectiveness were evident: Lavasept, Prontosan, and
Octenisept show a strong antibacterial effect in every concentration tested (1%–20%),
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Table 1. Antibacterialtestingoflocalantisepticagainstgram-positiveandgram-negativebacteria∗
Concentration, %
20 17.5 15 12.5 10 7.5 54321C o n t r o l
Braunol
Staphylococcus aureus ATCC 29213 + + + +
Enterococcus faecalis ATCC 29212 ++++ +
Escherichia coli ATCC 25922 ++++ +
Pseudomonas aeruginosa ATCC 27853 + + ++++ +
Betaisodona
Staphylococcus aureus ATCC 29213 + +
Enterococcus faecalis ATCC 29212 + + +
Escherichia coli ATCC 25922 + + +
Pseudomonas aeruginosa ATCC 27853 + ++++ +
Octenisept
Staphylococcus aureus ATCC 29213 +
Enterococcus faecalis ATCC 29212 +
Escherichia coli ATCC 25922 +
Pseudomonas aeruginosa ATCC 27853 +
Lavasept
Staphylococcus aureus ATCC 29213 +
Enterococcus faecalis ATCC 29212 +
Escherichia coli ATCC 25922 +
Pseudomonas aeruginosa ATCC 27853 +
Prontosan
Staphylococcus aureus ATCC 29213 +
Enterococcus faecalis ATCC 29212 +
Escherichia coli ATCC 25922 +
Pseudomonas aeruginosa ATCC 27853 +
∗Plus sign (+) indicates bacterial growth. Braunol showed antibacterial effect at a minimal concentration of 4% against S
aureus. At a concentration of 5%, E faecalis and Ec o l iwere inhibited, followed by P aeruginosa at 10%. Betaisodona shows
inhibitory effect against S aureus at 2% concentration. Antibacterial effect against E faecalis and Ec o l iwas detected at a
concentrationof3%,whereasaconcentrationof7.5%isnecessarytoobtaineffectivenessagainstPaeruginosa.ForLavasept,
Prontosan, and Octenisept, no bacterial growth could be detected.
whereas povidone-iodine–based antiseptics require higher concentrations to completely
inhibit bacterial growth (3%–7.5%; Table 1).
ENHANCED RESISTANCE AGAINST LOCAL ANTISEPTICS IN MRSA
STRAINS
Resistance of bacterial strains toward antibiotic agents is well described and well known
in daily healthcare needs. Hirsch et al16 investigated antibacterial efﬁcacy of PHMB-based
wound antiseptics and wound irrigants toward susceptible S aureus strains and MRSA.
Regular American Type Culture Collection (ATCC)-listed S aureus strains were com-
pared with MRSA strains (ATCC, Manassas, Va, and “International Basic Set,” Robert-
Koch-Institute, Wernigerode, Germany) with the PHMB-based products Prontosan and
Lavasept at a 0.005% concentration.
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For each of the 4 MRSA strains, highly signiﬁcant, elevated resistance toward the sus-
ceptible control strains was detected: MRSA strains showed an average 160-fold increased
resistance, with a maximum of 400-fold. This study shows that antibiotic-resistant S aureus
strains possess highly signiﬁcant, elevated resistance toward local antiseptics compared
with antibiotic-sensitive control strains.
CYTOTOXICITY
To assess cytotoxic effects of local skin antiseptics at different concentrations, cell tox-
icity (MTT) and proliferation (BrDU) assays were performed in our study mentioned
previously.15 Therefore, studies on primary human keratinocytes and ﬁbroblasts, as well
as HaCaT cell line, were performed (MTT assay and BrdU-ELISA) at 1% to 20% con-
centrations. In HaCaT cells, all skin antiseptics showed toxic effects toward the cells.
However, Lavasept and Prontosan induced only moderate toxicity, whereas Betaisodona
and Octenisept showed strong effects, followed by Braunol. These ﬁndings were conﬁrmed
in the primary human keratinocytes: Lavasept and Prontosan showed low toxicity, whereas
Betaisodona, Octenisept, and Braunol had signiﬁcant impact on cell viability (Fig 1).
Figure 1. Cytotoxicity of antiseptics in skin cells. (a) In HaCaT cells, Lavasept and Prontosan
show little toxicity. Betaisodona-treated cells show no vitality at a concentration of 12.5%, fol-
lowed by Octenisept at 15% and Braunol at 20%. (b) Human keratinocytes are barely affected
by Lavasept and Prontosan. Braunol and Octenisept show low cytotoxicity up to concentrations
of 12.5%, followed by a marked decrease in cytotoxicity. Betaisodona is the most toxic agent.
(c) In ﬁbroblast, Lavasept showed the best result. Prontosan showed low toxicity. Braunol has low
toxicity within low concentrations, followed by a linear decrease of 0% in cell viability. At 10%,
Octenisept shows a decrease of 0%, followed by Betaisodona (0% cell viability at 7.5%).
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To analyze the impact of skin antiseptics on proliferative activity of the cells, the
BrDU-ELISA assay was performed. The data show that Lavasept and Prontosan had little
to no effect on proliferative activity, whereas Betaisodona, Octenisept, and Braunol showed
signiﬁcant toxicity in all 3 cell types assessed (Betaisodona > Octenisept > Braunol).
Generally, it turns out that ﬁbroblasts are more susceptible to skin antiseptics than primary
keratinocytes and the keratinocyte cell line HaCaT. Taken these data together, 3 of 5 skin
antiseptics revealed signiﬁcant alterations regarding cell viability and proliferation.
Langer and coworkers17 investigated the inﬂuence of local antiseptics on skin mi-
crocirculation in vivo and reported that all antiseptics assessed (70% ethanol, Softasept,
Octenisept, and Lavasept) inﬂuenced skin microcirculation with regard to blood vessel
leakage, functional capillary density, and red blood cell velocity when compared with the
saline control. They reported that Octenisept had the least impact on microcirculatory
parameters.17 M¨ uller and Kramer18 investigated the antimicrobial effect of 12 different
skin antiseptics, including PVP-iodine, octenidine, and PHMB solutions, toward Ec o l iand
S aureus. At the same time, cytotoxic effects in ﬁbroblasts were analyzed. The authors
concluded that octenidine and PHMB solutions were the most suitable agents assessed in
their study.18 However, in an earlier study, the same authors stated that povidone-iodine
seems to be the most tolerated antiseptic in comparison with chlorhexidine, octenidine, or
PHMB solutions.19 Kalteis et al20 assessed the tissue compatibilities of Dibromol (sodium
3,5-dibromo-4-hydroxy benzenesulfonate), Kodan (propanol), Jodobac (povidone iodine),
Octenisept, 0.2% Lavasept, hydrogen peroxide, 0.5% chlorhexidine digluconate, and 60%
2-propanol in the hen’s egg test chorion-allantoic membrane (HET-CAM). The authors
found that the most severe tissue toxicity being induced by 0.5% chlorhexidine diglu-
conate and Kodan. Irritating values were determined for Dibromol, Octenisept, and 60%
2-propanol. Moderate vascular injuries were caused by Jodobac. Lavasept and hydrogen
peroxide showed no tissue toxicity.20
COMPATIBILITY
Aprimarystrategytopreventandtreatinfectioninchronicwoundsistheuseoftopicalanti-
septics,wound-irrigatingagents,andwounddressingsatthesametime.Interestingly,thein-
teraction of antiseptics with commonly used wound dressings is hardly investigated to date.
In a current study, we analyzed the antimicrobial activity of antiseptics and wound-
irrigating agents with commercially available wound dressings: Five clinically used anti-
septics and wound-irrigating agents (Prontosan, Lavasept, Braunol, Octenisept, and Be-
taisodona) were tested in the presence or absence of 42 wound dressings against S aureus.
Antibacterialactivitywasdeterminedbydiscdiffusionassay.Inthisstudy,povidone-iodine–
based products showed sufﬁcient antimicrobial activity in 64% to 78% of the combinations
assessed (P > .01). The octenidine derivative Octenisept showed sufﬁcient antimicrobial
activity in 54% of combinations. PHMB derivatives demonstrated sufﬁcient antimicro-
bial activity in 32% of the combinations. This study revealed that commonly used wound
dressingsdramaticallyreduceantibacterialactivityofclinicallyusedantisepticsandwound-
irrigating agents in vitro.21
Other studies have shown that modern wound dressings show no signiﬁcant improve-
ment in wound healing. A Cochrane meta-analysis of the topical treatment of wounds with
324HIRSCH ET AL
silver as the antimicrobial agent identiﬁed 3 randomized controlled clinical trials com-
prising a total of 847 participants. One trial compared silver-containing foam (Contreet)
with hydrocellular foam (Allevyn) in patients with leg ulcers, the second trial compared
a silver-containing alginate (Silvercel) with an alginate alone (Algosteril), and the third
trial compared the silver-containing foam Contreet with best local practice in patients with
chronic wounds. The data from these 3 trials demonstrated that silver-containing foam
dressings did not signiﬁcantly increase complete ulcer healing as compared with standard
foam dressings or best local practice after up to 4 weeks of follow-up, although a greater
reduction in ulcer size was observed with the silver-containing foam. The authors stated
that there is insufﬁcient evidence to recommend the use of silver-containing dressings for
the treatment of infected or contaminated chronic wounds.22 In a meta-analysis by Nelson
and Bradley,23 investigating dressings and topical agents for arterial leg ulcers to determine
whether topical agents and wound dressings affect the rate of healing in arterial ulcers,
only 1 trial met the inclusion criteria. This small trial compared ketanserin ointment with
vehicle alone. The trial was too small and the follow-up period was too short to be able to
determine whether there was any difference in healing rates.23 In another Cochrane review,
the authors performed an extensive literature search in the ﬁeld of dressings for healing
venous leg ulcers. Forty-two randomized controlled studies were identiﬁed that met the
inclusion criteria. The main dressing types that were evaluated were hydrocolloids (n = 23),
foams (n = 6), alginates (n = 4), hydrogel dressings (n = 6), and a group of miscellaneous
dressings (n = 3). There was no evidence that any particular dressing type was better than
any others in terms of number of ulcers healed. At present, the evidence base does not sug-
gest that hydrocolloids are more effective than simple low-adherent dressings used beneath
compression. For other comparisons, there was insufﬁcient evidence.
CONCLUSION
Antiseptics are used in hospitals worldwide to reduce, inactivate, or eliminate potentially
pathogenic microorganisms. Current studies show that widely used wound antisepticsshow
relevant cytotoxicity and cross-reactivity with wound dressings. Furthermore, antibiotic-
resistant S aureus strains (MRSA) show highly signiﬁcant, elevated resistance toward
local antiseptics. Future research should particularly focus on cytotoxicity, mechanisms of
bacterial resistance toward skin antiseptics, and wound irrigates, as well as compatibility
and cross-reactivity with wound dressings. The science of antiseptic activity and efﬁcacy
testing is complex and further research would beneﬁt patient care and prevent negative side
effects.
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